This is a preview of subscription content, log in via an institution to check access.
References
Nicolini FE, Corm S, Le QH, Sorel N, Hayette S, Bories D et al. Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP). Leukemia 2006; 20: 1061–1066.
Branford S, Rudzki Z, Walsh S, Parkinson I, Grigg A, Szer J et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003; 102: 276–283.
Soverini S, Martinelli G, Rosti G, Bassi S, Amabile M, Poerio A et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol 2005; 23: 4100–4109.
Ottesen EA, Hong JW, Quake SR, Leadbetter JR . Microfluidic digital PCR enables multigene analysis of individual environmental bacteria. Science 2006; 314: 1464–1467.
Baker SG, Kramer BS, McIntosh M, Patterson BH, Shyr Y, Skates S . Evaluating markers for the early detection of cancer: overview of study designs and methods. Clin Trials 2006; 3: 43–56.
Willis SG, Lange T, Demehri S, Otto S, Crossman L, Niederwieser D et al. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood 2005; 106: 2128–2137.
Branford S, Rudzki Z, Parkinson I, Grigg A, Taylor K, Seymour JF et al. Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood 2004; 104: 2926–2932.
Nardi V, Raz T, Cao X, Wu CJ, Stone RM, Cortes J et al. Quantitative monitoring by polymerase colony assay of known mutations resistant to ABL kinase inhibitors. Oncogene 2008; 27: 775–782.
Acknowledgements
This work was supported by NCI CA106796, Leukemia and Lymphoma Society Translational Research Grant and V Foundation for Cancer Research V Scholar Grant (VGO), NCI CA18029 (JPR) and the Canary Foundation (SA and FM).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Oehler, V., Qin, J., Ramakrishnan, R. et al. Absolute quantitative detection of ABL tyrosine kinase domain point mutations in chronic myeloid leukemia using a novel nanofluidic platform and mutation-specific PCR. Leukemia 23, 396–399 (2009). https://doi.org/10.1038/leu.2008.183
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2008.183
- Springer Nature Limited
This article is cited by
-
Qualitative and quantitative detection of surgical pathogenic microorganisms Escherichia coli and Staphylococcus aureus based on ddPCR system
Scientific Reports (2021)
-
Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia
BMC Cancer (2018)
-
Direct comparison of quantitative digital PCR and 2-hydroxyglutarate enantiomeric ratio for IDH mutant allele frequency assessment in myeloid malignancy
Leukemia (2015)
-
Single molecule detection in nanofluidic digital array enables accurate measurement of DNA copy number
Analytical and Bioanalytical Chemistry (2009)